Primo Nutraceuticals Inc. (CSE:PRMO,FWB:8BV) has launched its campaign on the Investing News Network’s cannabis channel.

Primo Nutraceuticals provides infrastructure and seed-to-sale services to licensed tenant cannabis growers in Washington state. The company owns a four-acre property in the Okanogan Valley in Washington state as well as senior water rights for the land. The property hosts a 10,000-square-foot greenhouse, which has been leased to a tenant grower. Primo Nutraceuticals is currently building out two additional 10,000-square-foot greenhouses on the property and intends to expand its land package by at least six acres.

Keep reading... Show less

1933 Industries Inc. (CSE:TGIF,OTCQX:TGIFF,FWB:IQF) CEO Chris Rebentisch recently joined the Stock Day podcast to discuss the company’s expansion plans, including a new 67,000-square-foot cannabis cultivation facility. Rebentisch also provided an overview of the company’s recent progress, including a partnership with skateboarding legend Tony Hawk.  

The company’s 67,000-square-foot, state-of-the-art indoor cultivation facility in Nevada is expected to increase 1933 Industries’ cultivation capacity by 500 percent. Rebentisch expects the first harvest from the facility to begin in December. As for the old facility, 1933 Industries intends to retrofit it to a 10,000-square-foot extraction facility, to ensure that the company can meet its current product quotas. According to Rebentisch, the company’s existing extraction facility is running for 16 hours per day to keep up with the current demand.

Keep reading... Show less

Harvest One Cannabis Inc. (TSXV:HVT, OTCQX:HRVOF) subsidiary Satipharm AG spoke about the proprietary Gelpell® technology during the Dublin Marathon Expo in Dublin, Ireland. Satipharm AG is a health and well-being company that specializes in the development and manufacturing of cannabinoid-based products.

Gelpell® technology is designed to help address the bioavailability and consistency issues associated with the delivery of orally-ingested cannabis-based products. Satipharm has completed clinical trials on the Gelpell® capsules with PhytoTech Therapeutics Limited (PTL).  Satipharm representative Matthew Gavin talked about CBD capsules and Gelpell® technology, and said, “it makes it 360 percent more effective than oils, so our phase one and phase two clinical trials showed us data that we can place cannabinoids into micro-gelatin spheres.”

Keep reading... Show less